Mullerian Inhibiting Substance inhibits invasion and migration of epithelial cancer cell lines-Reference-Cited by-同舟云学术

Mullerian Inhibiting Substance inhibits invasion and migration of epithelial cancer cell lines

Published:2011-01 Issue:1 Volume:120 Page:128-134
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Chang Henry L.,Pieretti-Vanmarcke Rafael,Nicolaou Fotini,Li Xianlin,Wei Xiaolong,MacLaughlin David T.,Donahoe Patricia K.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference45 articles.

1. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian Inhibiting Substance (MIS) type II receptor, bind, and are responsive to MIS;Masiakos;Clin Cancer Res,1999

2. Mullerian Inhibiting Substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway;Segev;J Biol Chem,2000

3. Mullerian Inhibiting Substance regulates NF-kappa B signaling in the prostate in vitro and in vivo;Segev;Proc Natl Acad Sci,2002

4. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer;Pieretti-Vanmarcke;Proc Natl Acad Sci,2006

5. Mullerian Inhibiting Substance: an instructive developmental hormone with diagnostic and possible therapeutic applications;Teixeira;Endocr Rev,2001

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Anti-Müllerian Hormone in Ovarian Function;Seminars in Reproductive Medicine;2024-03

2. The roles of anti-Müllerian hormone in breast cancer;Endocrine-Related Cancer;2023-07-06

3. Translational Physiology of Anti-Müllerian Hormone: Clinical Applications in Female Fertility Preservation and Cancer Treatment;Frontiers in Endocrinology;2021-09-07

4. The chorioallantoic membrane as a bio-barrier model for the evaluation of nanoscale drug delivery systems for tumour therapy;Advanced Drug Delivery Reviews;2021-07

5. Ovarian carcinoma: pathology review with an emphasis in their molecular characteristics;Chinese Clinical Oncology;2020-08